Intelligent Bio Solutions Announces Fiscal Q2 2025 Financial Results and Key Operational Achievements
13 févr. 2025 08h30 HE
|
Intelligent Bio Solutions, Inc.
Gross profit increase of 32.6% and 11-point gross profit margin increase driven by higher-margin cartridge sales Submitted FDA 510(k) and remain on track for planned expansion into multi-billion...
Intelligent Bio Solutions Releases Shareholder Letter Detailing 2024 Growth and 2025 U.S. Expansion Strategy
10 févr. 2025 08h30 HE
|
Intelligent Bio Solutions, Inc.
NEW YORK, Feb. 10, 2025 (GLOBE NEWSWIRE) -- Intelligent Bio Solutions Inc. (Nasdaq: INBS) (“INBS” or the “Company”), a medical technology company delivering intelligent, rapid, non-invasive testing...
Intelligent Bio Solutions Expands with UK Partnership, Driving Global Growth Ahead of Planned U.S. Launch
07 févr. 2025 08h30 HE
|
Intelligent Bio Solutions, Inc.
Avon Freight Group selects INBS’ fingerprint drug testing for three UK sites, reinforcing workplace safety and efficiency INBS surpasses 400+ accounts in 19 countries, targeting aggressive U.S....
Intelligent Bio Solutions expects to achieve 32.6% Gross Profit Expansion and Increased Profitability on Higher-Margin Sales
06 févr. 2025 09h00 HE
|
Intelligent Bio Solutions, Inc.
Gross profit expected to surge by 32.6% Unaudited revenue of $0.61 million for fiscal Q2 and $1.48 million for the six months ended December 31, 2024 Higher-margin cartridge sales driving...
Intelligent Bio Solutions Expands Global Reach with Multilingual Drug Screening System Upgrade
31 janv. 2025 09h00 HE
|
Intelligent Bio Solutions, Inc.
NEW YORK, Jan. 31, 2025 (GLOBE NEWSWIRE) -- Intelligent Bio Solutions Inc. (Nasdaq: INBS) (“INBS” or the “Company”), a medical technology company delivering intelligent, rapid, non-invasive testing...
Intelligent Bio Solutions Adds Quantum TM to 400+ Account Portfolio Utilizing Breakthrough Fingerprint Drug Testing
29 janv. 2025 09h00 HE
|
Intelligent Bio Solutions, Inc.
Quantum Traffic Management transitions from saliva and urine testing to non-invasive, in-house fingerprint sweat-based drug screening Most recent client added to INBS’s portfolio of more than 400...
Intelligent Bio Solutions Partners with IVY Diagnostics to Expand in Europe’s $3.6 Billion Drug Screening Market and in Middle Eastern Regions
28 janv. 2025 09h00 HE
|
Intelligent Bio Solutions, Inc.
NEW YORK, Jan. 28, 2025 (GLOBE NEWSWIRE) -- Intelligent Bio Solutions Inc. (Nasdaq: INBS) ("INBS" or the "Company"), a medical technology company delivering intelligent, rapid, non-invasive testing...
Intelligent Bio Solutions Partners with Princebuild to Transition from Saliva Testing to Fingerprint Sweat-Based Drug Screening Across its Seven UK Sites
14 janv. 2025 08h30 HE
|
Intelligent Bio Solutions, Inc.
Princebuild has moved from saliva testing to INBS' fingerprint drug testing solution to implement a more streamlined, in-house solution across seven sites.
Intelligent Bio Solutions Announces 510(k) Submission to US FDA for Fingerprint Sweat-Based Drug Screening Technology
18 déc. 2024 08h30 HE
|
Intelligent Bio Solutions, Inc.
NEW YORK, Dec. 18, 2024 (GLOBE NEWSWIRE) -- Intelligent Bio Solutions Inc. (Nasdaq: INBS) ("INBS" or the "Company"), a medical technology company delivering intelligent, rapid, non-invasive testing...
Intelligent Bio Solutions to Host Virtual Fireside Chat on Wednesday, December 11th at 4:30 p.m. ET
04 déc. 2024 08h30 HE
|
Intelligent Bio Solutions, Inc.
NEW YORK, Dec. 04, 2024 (GLOBE NEWSWIRE) -- Intelligent Bio Solutions Inc. (Nasdaq: INBS) (“INBS” or the “Company”), a medical technology company delivering intelligent, rapid, non-invasive testing...